By Josh White
Date: Thursday 23 May 2024
(Sharecast News) - Avacta Group announced the successful completion of the first cohort and the start of dosing for three patients in the second cohort of the second arm in its phase one trial of AVA6000, a peptide drug conjugate form of doxorubicin chemotherapy, on Thursday.
By Josh White
Date: Thursday 21 Mar 2024
(Sharecast News) - Avacta Group announced a significant milestone in its phase 1a dose escalation study of AVA6000, its lead 'preCISION' drug, on Thursday.
By Michele Maatouk
Date: Thursday 29 Feb 2024
(Sharecast News) - Healthcare therapeutics company Avacta tumbled on Thursday after a heavily discounted placing.
Currency | UK Pounds |
Share Price | 41.25p |
Change Today | 0.25p |
% Change | 0.61 % |
52 Week High | 159.60 |
52 Week Low | 40.40 |
Volume | 1,043,341 |
Shares Issued | 359.04m |
Market Cap | £148.10m |
RiskGrade | 461 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 2 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 1 |
Total | 3 |
No dividends found |
Time | Volume / Share Price |
17:06 | 35,000 @ 41.25p |
16:34 | 100,000 @ 41.00p |
16:29 | 1,000 @ 41.35p |
16:29 | 3,000 @ 41.35p |
16:28 | 5,000 @ 41.35p |
CFO | Tony Peter Gardiner |
CEO | Christina Coughlin |
You are here: research